CN1646120A - Antineoplastic combinations - Google Patents
Antineoplastic combinations Download PDFInfo
- Publication number
- CN1646120A CN1646120A CNA02811048XA CN02811048A CN1646120A CN 1646120 A CN1646120 A CN 1646120A CN A02811048X A CNA02811048X A CN A02811048XA CN 02811048 A CN02811048 A CN 02811048A CN 1646120 A CN1646120 A CN 1646120A
- Authority
- CN
- China
- Prior art keywords
- tumor
- rapamycin
- mtor inhibitor
- cancer
- alkylating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940046044 combinations of antineoplastic agent Drugs 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 48
- 229940100198 alkylating agent Drugs 0.000 claims abstract description 48
- 239000002168 alkylating agent Substances 0.000 claims abstract description 48
- 229940124302 mTOR inhibitor Drugs 0.000 claims abstract description 48
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims abstract description 48
- 229960002930 sirolimus Drugs 0.000 claims description 52
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 51
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 50
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 45
- 229960000235 temsirolimus Drugs 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 40
- 230000000259 anti-tumor effect Effects 0.000 claims description 36
- -1 ethyl rapamycin Chemical compound 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 18
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 17
- 229960004397 cyclophosphamide Drugs 0.000 claims description 14
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 11
- 229960004316 cisplatin Drugs 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 9
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 7
- 229960001924 melphalan Drugs 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 201000008275 breast carcinoma Diseases 0.000 claims description 6
- 229960004562 carboplatin Drugs 0.000 claims description 6
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 6
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 6
- 229960004857 mitomycin Drugs 0.000 claims description 6
- 229930192474 thiophene Natural products 0.000 claims description 6
- HDCUSMZVZWLDRZ-UHFFFAOYSA-N 1-benzyl-2-methylhydrazine Chemical compound CNNCC1=CC=CC=C1 HDCUSMZVZWLDRZ-UHFFFAOYSA-N 0.000 claims description 5
- 229930192392 Mitomycin Natural products 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 5
- 229960005243 carmustine Drugs 0.000 claims description 5
- 229960004630 chlorambucil Drugs 0.000 claims description 5
- 229960001101 ifosfamide Drugs 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 201000001514 prostate carcinoma Diseases 0.000 claims description 5
- 229960004964 temozolomide Drugs 0.000 claims description 5
- IGMMTYZWNUSEEU-UHFFFAOYSA-N 3-(2-chloroethyl)-1-cyclohexyl-1-nitrosourea Chemical compound ClCCNC(=O)N(N=O)C1CCCCC1 IGMMTYZWNUSEEU-UHFFFAOYSA-N 0.000 claims description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 229960002092 busulfan Drugs 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 4
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 4
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 4
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000010174 renal carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 208000012991 uterine carcinoma Diseases 0.000 claims description 4
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 229940015849 thiophene Drugs 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 150000002148 esters Chemical class 0.000 description 15
- 230000003203 everyday effect Effects 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 10
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000008485 antagonism Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 5
- 101150108975 Rhd gene Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 150000007857 hydrazones Chemical class 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 150000002923 oximes Chemical class 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 239000007935 oral tablet Substances 0.000 description 4
- 229940096978 oral tablet Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 229960004961 mechlorethamine Drugs 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229940100691 oral capsule Drugs 0.000 description 3
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 101150097381 Mtor gene Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 229940098174 alkeran Drugs 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009096 combination chemotherapy Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- AAFJXZWCNVJTMK-GUCUJZIJSA-N (1s,2r)-1-[(2s)-oxiran-2-yl]-2-[(2r)-oxiran-2-yl]ethane-1,2-diol Chemical compound C([C@@H]1[C@H](O)[C@H](O)[C@H]2OC2)O1 AAFJXZWCNVJTMK-GUCUJZIJSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DMXNPMSYWQZJQJ-UHFFFAOYSA-N 1-(2-chloroethyl)-3-cyclohexyl-3-methyl-1-nitrosourea Chemical compound ClCCN(N=O)C(=O)N(C)C1CCCCC1 DMXNPMSYWQZJQJ-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920002160 Celluloid Polymers 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 206010061188 Haematotoxicity Diseases 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 239000011542 SDS running buffer Substances 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001032 anti-candidal effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940108502 bicnu Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940112133 busulfex Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229940090411 ifex Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229940063725 leukeran Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229940087732 matulane Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- JABGXPCRNXUENL-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1N=CNC2=NC=N[C]12 JABGXPCRNXUENL-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229940116399 mitomycin 20 mg Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- 229940090009 myleran Drugs 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N purine-6-thione Natural products S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 150000003921 pyrrolotriazines Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102220112717 rs770960237 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- ALZJERAWTOKHNO-UHFFFAOYSA-M sodium;dodecyl sulfate;3-morpholin-4-ylpropane-1-sulfonic acid Chemical compound [Na+].OS(=O)(=O)CCCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O ALZJERAWTOKHNO-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention provides the use of a combination of an mTOR inhibitor and an antinoeplastic alkylating agent in the treatment of neoplasms.
Description
The present invention relates to the application for the treatment of in the tumor that is combined in of mTOR inhibitor (for example 42-ester (CCI-779) of rapamycin and 3-hydroxyl-2-(hydroxymethyl)-2 Methylpropionic acid) and anti-tumor alkylating agent, the application in the medicine of preparation treatment tumor of mTOR inhibitor and anti-tumor alkylating agent, be used for the treatment of mammal tumor with simultaneously, combination formulations form independent or sequential use comprises the product of mTOR inhibitor and anti-tumor alkylating agent, and comprise the mTOR inhibitor, the pharmaceutical composition of anti-tumor alkylating agent and pharmaceutically suitable carrier.
Background technology
Rapamycin is a kind of macro ring trienes antibiotic that is produced by the moisture absorption streptomycete, finds that it all has antifungal activity in vitro and in vivo, particularly has activity [people such as C.Vezina, J.Antibiot.28,721 (1975) to anti-candida albicans; People such as S.N.Sehgal, J.Antibiot.28,727 (1975); People such as H.A.Baker, J.Antibiot.31,539 (1978); US 3,929, and 992; With US 3,993,749].In addition, separately (US 4,885,171) or have anti-tumor activity have been shown with the rapamycin of Streptococcus hemolyticus associating (US 4,401,653).
The immunosuppressive action of rapamycin is disclosed in FASEB 3,3411 (1989).Also showing cyclosporin A and other macrocycle molecule---FK-506 is effectively as immunosuppressant, and therefore, it can be used for preventing the rejection transplanted, and [FASEB 3,3411 (1989); FASEB3,5256 (1989); People such as R.Y.Calne, Lancet 1183 (1978); And US5,100,899].People such as R.Martel [Can.J.Physio.Pharmacol.55,48 (1977)] disclose rapamycin at a kind of model that is used for multiple sclerosis---experimental allergic encephalomyelitis model; At a kind of model that is used for rheumatoid arthritis---the adjuvant arthritis model all is effectively, and can suppress the formation of class-IgE antibody effectively.
Rapamycin also can be used for prevention or treatment systemic lupus erythematosus [US 5,078,999], [US 5 for pneumonia, 080,899], [US 5,321 for insulin dependent diabetes mellitus (IDDM), 009], dermatosis, [US 5,286 as psoriasis, 730], internal organs disease [US 5,286,731], [US 5 for inner membrance thickening behind smooth muscle cell proliferation and the blood vessel injury, 288,711 and 5,516,781], [EP 525 for Adult T-cell leukemia/lymphoma, 960 A1], eyes inflammation [US 5,387,589], [US 5 for pernicious cancer, 206,018], heart inflammatory diseases [US 5,496,832], and anemia [US5,561,138].
The 42-ester (CCI-779) that has proved rapamycin and 3-hydroxyl-2-(hydroxymethyl)-2 Methylpropionic acid is all tumor growth to be had remarkable inhibiting rapamycin esters in the model in vitro and in vivo.At US 5,362, the preparation and the application of the hydroxy ester of the rapamycin that comprises CCI-779 are disclosed in 718.
CCI-779 shows and the diverse cyto-inhibition of cytotoxicity, and can postpone the time of the development time or the tumor recurrence of tumor.Think that CCI-779 has the mechanism of action similar to the mechanism of action of sirolimus.CCI-779 combines with plasmosin FKBP and forms a species complex with it, and it has suppressed a kind of enzyme, mTOR (the mammal target of rapamycin is also referred to as and FKBP12-rapamycin proteins associated [FRAP]).Inhibitory action to the kinase activity of mTOR has suppressed many signal transduction pathways, thereby suppressed carry out of cell cycle from G1 to S, wherein said transduction pathway comprises that cytokine-stimulated cell proliferation, mRNA are for the translation of the key protein of some cell cycle regulation G1 phases with IL-2-is inductive transcribes.The mechanism of action of CCI-779 that can produce G1-S phase conduction block is for anticarcinogen and Yan Shixin.
External, CCI-779 has shown the growth that can suppress many tumor cells that break up on tectology.Nervous system (CNS) cancer, leukemia (T-cell), breast carcinoma, carcinoma of prostate and melanoma system are in the most responsive material of CCI-779 some.This chemical compound has suppressed the interim cell of G1 of cell cycle.
Carry out in the body research with nude mice and proved that CCI-779 has the activity of people's tumor xenogeneic graft of the various tissue morphology types of antagonism.Glioma is effective in nude mice normotopia glioma model for CCI-779 sensitivity especially and this chemical compound.CCI-779 can significantly suppress the growth in vitro factor (the platelet source)-inductive people's glioblastoma cell line.CCI-779 has also suppressed some pancreas tumores in one of the intravital growth of nude mice and two kinds of breast carcinoma systems growth in vivo.
Summary of the invention
The invention provides the application of the combination of mTOR inhibitor and anti-tumor alkylating agent as the antineoplastic combination chemotherapy.These combinations particularly can be used for treating neuroendocrine tumor, cervical cancer, uterus carcinoma, a neck cancer, glioma, nonsmall-cell lung cancer, carcinoma of prostate, cancer of pancreas, lymphoma, melanoma, small cell lung cancer, ovarian cancer, colon cancer, esophageal carcinoma, gastric cancer, leukemia, colorectal carcinoma and the unknown primary carcinoma of renal carcinoma, soft tissue cancer, breast carcinoma, lung.The present invention also provides as the mTOR inhibitor of antitumor combination chemotherapy and the combination of anti-tumor alkylating agent, and any dosage or the dosage of mTOR and anti-tumor alkylating agent all are inferior treatment effective doses in wherein used mTOR inhibitor or the anti-tumor alkylating agent.
On the other hand, the invention provides the application for preparing in the medicine for the treatment of tumor that is combined in of mTOR inhibitor and anti-tumor alkylating agent.On the other hand, the invention provides a kind of be used for the treatment of mammal tumor with simultaneously, separately or the combination formulations form of sequential use comprise the product of mTOR inhibitor and anti-tumor alkylating agent.Still in yet another aspect, the invention provides the pharmaceutical composition of a kind of mTOR of comprising inhibitor, anti-tumor alkylating agent and pharmaceutically suitable carrier.
Said term " treatment " refers to by giving said mammal effective dose mTOR inhibitor and anti-tumor alkylating agent to come the mammal that suffers from the tumor disease is handled to suppress such mammiferous tumor growth, eradicate tumor or to alleviate this mammiferous misery among the present invention.
As used in the present invention, carry out administration relating to prodrug, derivant or the analog of one or both components that term when giving this combination " gives " to refer to this combination of the effective dose that directly this combination is carried out administration or will can be formed this combination in vivo.
MTOR is the target of rapamycin in mammal, and it is also referred to as the albumen [FRAP] relevant with the FKBP12-rapamycin.Inhibitory action to the kinase activity of mTOR has suppressed many signal transduction pathways, thereby suppressed cell cycle from the carrying out of G1 to S, wherein said signal transduction pathway comprises cytokine-stimulated cell proliferation, and mRNA is for transcribing that the translation of the key protein of some cell cycle regulation G1 phases and IL-2-bring out.
MTOR is controlling at least two kinds of related in the translation of specific cells cycle regulating protein proteic activity (Burnett, P.E., PNAS 95:1432 (1998) and Isotani, S., J.Biol.Chem.274:33493 (1999)).A kind of in these albumen p70s6 kinases by mTOR phosphorylation on serine 389 and threonine 412.The Western blotting of the whole cell extract of these cells by having phosphoserine 389 residue specific antibodies can be observed this phosphorylation in the cell that somatomedin is handled.
" the mTOR inhibitor " that the present invention is used can be by the chemical compound or the part of the process inhibition cellular replication of blocking-up cell cycle from G1 to S thereby refer to, and the process of wherein said blocking-up cell cycle from G1 to S is the phosphorylation of the kinase whose serine 389 of p70s6 to be carried out by mTOR by inhibition.
Whether can measure defined chemical compound here with following standard pharmacology test method is the mTOR inhibitor.As by Western blotting proved, with the thunderous handkerchief mycin of mTOR inhibitor the cell of factors stimulated growth is handled the phosphorylation that can block serine 389 fully, said Western blotting has been formed the inhibiting good test of a kind of mTOR of being used for.Therefore, should not show a kind of bands of a spectrum in the whole cell lysates that exists the somatomedin of cultivating under the mTOR inhibitor situation of using by oneself (for example IGF1) to carry out stimulated cells on acrylamide gel, wherein said acrylamide gel can carry out labelling with the antibody of the serine 389 that is specific to p70s6K.
Material:
NuPAGE LDS sample buffer (Novex Cat#NP0007)
NuPAGE sample Reducing agent (Novex Cat#NP0004)
NuPAGE 4-12%Bis-Tris gel (Novex Cat#NP0321)
NuPAGE MOPS SDS Running buffer (Novex Cat#NP0001)
Celluloid (Novex Cat#LC2001)
NuPAGE transfering buffering liquid (Novex Cat#NP0006)
Hyperfilm?ECL(Amersham?Cat#RPN3114H)
ECL Western blotting detectable (Amersham Cat#RPN2134)
First antibody: phosphoric acid-p70 S6 kinases (Thr389) (Cell Signaling Cat#9205)
Second antibody: goat resists-rabbit igg-HRP complex (Santa Cruz Cat#sc-2004)
Method:
A. the preparation of cell lysates
Cell line is grown in the optimal basal medium that has added 10% hyclone and penicillin/streptomycin in addition.For phosphorylation research, with the cell cultivation of in 6 orifice plates, going down to posterity.After cell adheres to fully, make its serum starvation.With the mTOR inhibitor it was handled 2 to 16 hours.After carrying out drug treating, this cell is cleaned once with PBS (phosphate buffered saline (PBS) that does not have Mg++ and Ca++), then it is dissolved in 150-200 μ lNuPAGE LDS sample buffer.Lysate is promptly carried out ultrasonic, then with its under 14000rpm centrifugal 15 minutes.Lysate is stored until use under subzero 80 ℃.
Can also carry out this test operation yesterday by after it adheres to fully, this cell being cultivated one in growth medium.The gained result should be identical for the mTOR inhibitor under two cover conditions.
B. western blot analysis
1) prepares the total protein sample to wherein adding 2.5 μ l NuPAGE sample Reducing agents then by in each test tube, placing 22.5 μ l lysates.This sample was heated 10 minutes down at 70 ℃.Carry out electrophoresis with NuPAGE gel and NuPAGE SDS buffer.
2) with the NuPAGE transfering buffering liquid gel is transferred on the nitrocellulose filter.This film was blocked 1 hour with blocking-up buffer (the Tris buffer saline that has 0.1% tween and 5% defatted milk).With cleaning buffer solution (the Tris buffer saline that has 0.1% tween) film is cleaned twice.
3) under 4 ℃, P-p70 S6K (T389) first antibody (1: 1000) that on rotation platform trace/film is used in the blocking-up buffer is cultivated a night.
4) trace is washed with cleaning buffer solution, clean 3 times, cleaned 10 minutes at every turn, the second antibody (1: 2000) that then it is used in the blocking-up buffer was at room temperature cultivated 1 hour.
5) with after second antibody combines, trace is cleaned with cleaning buffer solution, clean 3 times, the each cleaning 10 minutes cleaned with the Tris buffer saline then, cleans 2 times, the each cleaning 1 minute carried out chemiluminescence (ECL) detection subsequently and also then the chemiluminescence film exposed.
Used term " rapamycin " has defined the immunosuppressive compounds that a class comprises basic rapamycin nucleus (as follows) among the present invention.Rapamycin of the present invention comprises can be by the chemical compound of this rapamycin nucleus derivative form of chemistry or biological modification, and this chemical compound still has inhibitive ability of immunity.Therefore, term " rapamycin " comprise ester, ether, oxime, hydrazone and the hydroxylamine of rapamycin and wherein the functional group on the rapamycin nucleus be modified the rapamycin that is modified by reduction or oxidation for example.Term " rapamycin " also comprises the pharmaceutically useful salt of rapamycin, and it can form salt by acidity or the basic moiety that comprises.
Rapamycin
Preferably, the ester of rapamycin and ether are the ester and the ether (electronation by 27-ketone obtains) of the ester of the 42-of rapamycin nucleus and/or 31-position hydroxyl and ether, 27-position hydroxyl, and preferably oxime, hydrazone and hydroxylamine are the ketone (by the 42-hydroxyl oxidize is obtained) on 42 of the rapamycin nucleus and oxime, hydrazone and the hydroxylamine of 27-ketone.
Following patent discloses 42-and/or the 31-ester and the ether of preferred rapamycin, and it here all is introduced into as a reference: Arrcostab (US 4,316,885); Aminoalkyl ester (US4,650,803); Fluorinated esters (US 5,100,883); Carboxylic acid amide esters (US 5,118,677); Carbamate (US 5,118,678); Silyl ether (US 5,120,842); Amino ester (US5,130,307); Acetal (US 5,51,413); Amino diester (US 5,162,333); Sulphonic acid ester and sulfuric ester (US 5,177,203); Ester (US 5,221,670); Alkoxy ester (US5,233,036); The O-aryl ,-alkyl ,-alkenyl and-alkynyl ether (US 5,258,389); Carbonic ester (US 5,260,300); Aryl carbonyl and alkoxycarbonyl amino formic acid esters (US5,262,423); Carbamate (US 5,302,584); Hydroxy ester (US 5,362,718); Ester (US 5,385,908) is obstructed; Heterocyclic ester (US 5,385,909); Together with-dibasic ester (US5,385,910); Amino-alkane acid esters (US 5,389,639); Phosphoryl carbamate (US5,391,730); Carbamate (US 5,411,967); Carbamate (US 5,434,260); Amidino groups carbamate (US 5,463,048); Carbamate (US 5,480,988); Carbamate (US 5,480,989); Carbamate (US 5,489,680); N-oxide ester (US 5,491,231) is obstructed; Biotin ester (US 5,504,091); O-alkyl ether (US 5,665,772); PEG ester (US 5,780,462) with rapamycin.The preparation of these esters and ether is disclosed in the listed in the above patent.
At US 5,256, preferred rapamycin 27-ester and ether are disclosed in 790, this patent here is introduced into as a reference.The preparation of these esters and ether is disclosed in the listed in the above patent.
At US 5,373, oxime, hydrazone and the hydroxylamine of preferred rapamycin disclosed in 014,5,378,836,5,023,264 and 5,563,145, these patents here are introduced into as a reference.The preparation of these oximes, hydrazone and hydroxylamine is disclosed in the listed in the above patent.5,023, the preparation of 42-oxo rapamycin is disclosed in 263, this patent here is introduced into as a reference.
Particularly preferred rapamycin class material comprises the 42-ester that rapamycin [US 3,929,992], CCI-779[rapamycin and 3-hydroxyl-2-(hydroxymethyl)-2 Methylpropionic acid form, and [US 5,362,718] and 42-O-(2-hydroxyl) ethyl rapamycin [US 5,665,772].
When using, when rapamycin comprises suitable basic moiety, can form the officinal salt of rapamycin with organic acid and mineral acid, wherein said acid is acetic acid, propanoic acid, lactic acid, citric acid, tartaric acid, succinic acid, fumaric acid, maleic acid, malonic acid, mandelic acid, malic acid, phthalic acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulphuric acid, methanesulfonic acid, LOMAR PWA EINECS 246-676-2, benzenesulfonic acid, toluenesulfonic acid, camphorsulfonic acid and similar known available acid for example.When rapamycin comprises the proper acidic part, can also form salt with organic and inorganic base, as alkali metal salt (for example, sodium, lithium or potassium salt), alkali salt, ammonium salt, in each alkyl, comprise the alkylammonium salt of 1-6 carbon atom or in each alkyl, comprise the dialkyl ammonium salt of 1-6 carbon atom and the trialkyl ammonium salts that in each alkyl, comprises 1-6 carbon atom.
Preferably, the mTOR inhibitor that is used for antitumor combination of the present invention is a rapamycin, and this mTOR inhibitor more preferably is rapamycin, CCI-779 or 42-O-(2-hydroxyl) ethyl rapamycin.
So as described herein-in, in mTOR inhibitor of the present invention adds the combination of antimetabolite, CCI-779 is evaluated as a kind of representational mTOR inhibitor.
At US 5,362, the preparation to CCI-779 in 718 is described, and this patent here is introduced into as a reference.When CCI-779 was used as antitumor agent, when being the basis with daily dose scheme (administration every day, successive administration 5 days carries out once such administration every 2-3 week), the vein input dosage that it is initial was designed to about 0.1 to 100mg/m
2, and when with the dosage that is administered once weekly being basis when carrying out administration, this dosage is about 0.1 to 1000mg/m
2The input of oral or vein is preferred route of administration, and more preferably intravenous administration.
Term used herein " anti-tumor alkylating agent " refers in cell that atom with many electron riches reacts (or " alkylation ") thereby the material that forms covalent bond.The most important reaction relevant with its anti-tumor activity is the reaction with the DNA base.Some alkylating agents are alkylating agents of simple function group, and it only can react with the chain of DNA.Some other is a difunctional, thereby can react two chains covalently bound " crosslinked " that form a kind of dna double spiral with the atom on each bar chain in two chains of DNA.Unless be repaired, otherwise this infringement will make cell effectively not duplicate.The lethal of simple function group alkylating agent is owing to the reaction to this infringement produces to the identification of the impaired property of DNA cell infringement and cell.(Colvin OM. anti-tumor alkylating agent .Cancer Principles ﹠amp; Practice ofOncology, the 6th edition, chief editor: DeVita VT, Hellman S, Rosenberg SA.Lippincott Williams ﹠amp; 2001,363 pages of Wilkins.Philadelphia.)
Usually structure and the reactive moieties according to anti-tumor alkylating agent is divided into several classes, and it comprises nitrogen mustards, as mechlorethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil; Azidines and epoxide replace group, ametycin, NSC-132313 and mitolactol as thiophene; Alkyl sulfonates is as busulfan; Nitrosoureas is as carmustine (BCNU), cyclohexyl-chlorethylnitrosourea (CCNU) and methylcyclohexyl chlorethylnitrosourea (MeCCNU); Hydrazine and pyrrolotriazine derivatives are as methylbenzyl hydrazine, dacarbazine and temozolomide; And platinum compounds.Platinum compounds is to comprise the platinum that preferentially reacts on the N7 position of guanine and adenine residue with the material that forms various simple function groups and difunctional adduct.(JohnsonSW, Stevenson JP, O ' Dwyer PJ. cisplatin and analog thereof. at CancerPrinciples; Practice of Oncology, in the 6th edition, chief editor DeVitaVT, Hellman S, Rosenberg SA.Lippincott Williams ﹠amp; 2001.378 pages of Wilkins.Philadelphia.) these chemical compounds comprise cisplatin, carboplatin, platinum IV chemical compound and multinuclear platinum complex.
Be the representational example of anti-tumor alkylating agent of the present invention below.
Mechlorethamine can obtain by commercial sources with injectable forms (MUSTARGEN).
Cyclophosphamide can obtain by commercial sources with the form (cyclophosphamide or CYTOXAN) of injectable forms (cyclophosphamide, cryodesiccated CYTOXAN or NEOSAR) and oral tablet.
Ifosfamide can obtain by commercial sources with injectable form (IFEX).
Melphalan can obtain from commercial channels with the form (ALKERAN) of injectable form (ALKERAN) and oral tablet.
Chlorambucil can obtain by commercial sources with the form (LEUKERAN) of oral tablet.
Thiophene can obtain by commercial sources with injectable form (thiophene is for group or THIOPLEX) for group.
Mitomycin can obtain by commercial sources with injectable form (mitomycin or MUTAMYCIN).
Busulfan can obtain by commercial sources with the form (MYLERAN) of injectable form (BUSULFEX) and oral tablet.
Chlorethyl cyclohexyl nitrosourea (CCNU) can obtain by commercial sources with the form (CEENU) of oral capsule.
Carmustine (BCNU) can obtain by commercial sources with the form (GLIADEL) and the injectable form (BICNU) of intracranial implant.
The methylbenzyl hydrazine can obtain by commercial sources with the form (MATULANE) of oral capsule.
The temozolomide can obtain by commercial sources with the form (TEMODAR) of oral capsule.
Cisplatin can obtain by commercial sources with injectable form (cisplatin, PLATINOL or PLATINOL-AQ).
Carboplatin can obtain by commercial sources with injectable form (PARAPLATIN).
Following table has been summarized the recommended dose of listed anti-tumor alkylating agent above some briefly.
The recommended dose of table 1. anti-tumor alkylating agent
Medicine | Dosage | Scheme |
Mechlorethamine | 0.4mg/kg | Each process is carried out with 0.1 to 0.2mg/kg/ day single dose or separation dosage |
Cyclophosphamide | 40-50mg/kg, i.v. 10-15 mg/kg, i.v. 3-5mg/kg, i.v. 1-5mg/kg is oral | In 2-5 days time, carried out being administered once and be administered twice every day weekly every 7-10 days to separate dosage |
Ifosfamide | 1.2g/m 2,i.v. | Administration every day in continuous 5 day; Every repeating once in 3 weeks or after hematotoxicity recovers, repeating |
Melphalan | 6mg, oral 10mg, oral 0.15mg/kg, oral 16mg/m 2,i.v. ? ? ? | Administration every day in 2-3 week, 4 weeks at interval afterwards, 2mg maintenance dose every day interior administration every day in 7-10 days then, administration every day in cytometry recovers back 2mg maintenance dose every day 7 days afterwards, drug withdrawal afterwards at least 14 days, keep once with the daily dose of 0.005mg/kg every day then every 2 all infusions, administration in 15-20 minute, be administered four times, be the rest period afterwards, carry out administration to keep with interval all around then |
Chlorambucil | 0.1-0.2 mg/kg is oral | Administration every day, administration 3-6 week |
Thiophene is for group | 0.3-0.4 mg/kg,i.v. | Be administered once every 1-4 week |
Mitomycin | 20mg/m 2,i.v. | Be administered once every 6-8 week |
Busulfan | 1.8mg/m 2, oral | Administration every day |
Chlorethyl cyclohexyl nitrosourea | 130mg/m 2, oral | Be administered once every 6 weeks |
Carmustine | 150-200mg/m 2, i.v. | Be administered once every 6 weeks |
The methylbenzyl hydrazine | 2-4mg/kg, oral 1-2mg/kg, oral | First week administration every day, 4-6mg/kg keeps until obtaining maximum reaction then |
The temozolomide | 150mg/m 2, oral | Be administered once every day in 5 days, and per 28 days is a treatment cycle |
Cisplatin | 20mg/m 2,i.v. 75-100mg/m 2, i.v. | Be administered once and be administered once every the cycle all around 5 day every day in each cycle |
Carboplatin | 360mg/m 2,i.v. | Be administered once every the cycle all around |
The combination that the preferred mTOR inhibitor of the present invention adds anti-tumor alkylating agent comprises that CCI-779 adds cisplatin; CCI-779 adds cyclophosphamide; CCI-779 adds carboplatin; Add BCNU with CCI-779.
As representative mTOR inhibitor, add cisplatin with CCI-779 in the standard pharmacological method with CCI-779 in vitro and in vivo; CCI-779 adds cyclophosphamide; Adding BCNU with CCI-779 proves conclusively the anti-tumor activity that this mTOR inhibitor adds the anti-tumor alkylating agent combination as the representational combination of the present invention.Below method therefor and gained result briefly are described.
With the human rhabdomyosarcoma is that Rh30 and Rh1 and people's glioblastoma are the external combination research that SJ-GBM2 carries out CCI-779 and alkylating agent.What research was used in the body is that people's neuroblastoma (NB1643) and human colon carcinoma are GC3.
Measure the dose response curve of various interested medicines.With cell line Rh30, Rh1 and SJ-G2 respectively with 6 * 10
3, 5 * 10
3With 2.5 * 10
4The quantity of individual cells/well is seeded on a kind of 6 hole flat boards.After it is cultivated 24 hours, medicine is joined the 10%FBS+RPMI 1640 that is used for Rh30 and Rh1 or joins the 15%FBS+DME that is used for SJ-G2.With it with after the culture medium that comprises medicine contacts 7 days, by using hypisotonic solution, handle with a kind of detergent pair cell that then nuclear being released.With the Coulter enumerator nuclear is counted then.With experimental result mapping and determine the IC of each medicine by extrapolation
50(growth is produced 50% drug level that suppresses).Because the IC between experiment and the experiment
50Value is slightly different, so use the IC with each medicine in Study of Interaction
50Draw together two values together.When its with 1: if identical trunk (isobole) is a standard shape when 1 ratio exists, interactional maximum point between two kinds of medicines then appears.Therefore, with three kinds of approaching IC of CCI-779
50Concentration is separately respectively with ratio and cisplatin, BCNU and three kinds of close IC of melphalan of 1: 1
50In various the mixing.It has produced nine kinds of medicines of respectively testing of 1: 1 and has added three kinds of IC of CCI-779
50The combination of concentration and other medicines.To comprising IC
50Each medicine of value, this scheme produce at least a combination usually.Then, use Berenbaum ' s formula: x/X50+y/Y50=1,<1,>1 calculates each IC of CCI-779
50Additivity, synergism or the antagonism of concentration and 1: 1 combination of various chemotherapeutics.If three kinds of concentration of the CCI-779 that tests separately do not have three kinds of IC of generation and other chemical compound of testing separately
50In any IC that is complementary, then all combinations of 1: 1 are all checked to check whether its IC value drops between the suitable IC value of the medicine of testing respectively.If the way it goes, think that then this effect has additivity.
The result of gained shows in external standard pharmacology test operation, and when testing with Rh30 tumor system, the combination that CCI-779 adds cisplatin has concertedness; The effect of this combination is higher than additivity but does not reach concertedness on mathematics during antagonism Rh1 tumor cell line, and has additivity when resisting the SJ-G2 tumor cell line.CCI-779 add BCNU be combined in antagonism SJ-G2 tumor cell line the time have concertedness, it is higher than additivity but does not but reach the concertedness level on mathematics during antagonism Rh30 cell line, and has additivity when antagonism Rh1 cell line.The combination that CCI-779 adds melphalan resists various cell lines all additivity.
(ME) forfeiture immunity is then at 3 Zhou Houyong for JacksonLaboratories, Bar Harbor to make big female CBA/CaJ mice of 4 weeks by thymectomy
137Integral body radiation (1200cGy) is carried out to it in the Cs source.6-8 hour mice accepts 3 * 10 after radiation
6Individual nuclear medullary cell.Will about 3mm
3Tumor mass be transplanted in the dorsal part rib abdominal cavity of mice so that tumor begins growth.Before beginning to treat, mice with tumor is divided into seven groups at random.When diameter of tumor reaches about 0.20-1cm, carry out administration for each mice with tumor.The tumor size is measured with 7 days interval with the digital vernier caliper that joins with computer.Suppose that tumor is spherical, with formula [(π/6) * d
3] calculate gross tumor volume, wherein d is an average diameter.According to successive administration 5 days, two all time of administration tables carried out administration with CCI-779, repeat this cycle every 21 days, carry out 3 cycles.This makes CCI-779 1-5,8-12 days (cycle 1); 21-25,28-32 days (cycle 2); Be carried out administration during with 42-46,49-53 days (cycle 3).It is as follows that each studies other chemotherapeutics time of administration table:
Cyclophosphamide carried out administration at the 1st day and the 8th day, repeated this cycle in per 21 days, carried out 3 cycles
With human rhabdomyosarcoma (Rh18), the combination of CCI-779 and cyclophosphamide is assessed with above-mentioned mice xenotransplantation test method(s).In this test operation, the effect of CCI-779 and cyclophosphamide (44mg/kg) has additivity.When not to be optimal dosage when carrying out coupling, CCI-779 adds the cyclophosphamide that cyclophosphamide equals to carry out with optimal dose administration.
According to the result of these standard pharmacology test operations, the combination that the mTOR inhibitor adds anti-tumor alkylating agent can be used for antineoplaston.More particularly, these combinations can be used for treating neuroendocrine tumor, cervical cancer, uterus carcinoma, a neck cancer, glioma, nonsmall-cell lung cancer, carcinoma of prostate, cancer of pancreas, lymphoma, melanoma, small cell lung cancer, ovarian cancer, colon cancer, esophageal carcinoma, gastric cancer, leukemia, colorectal carcinoma and the unknown primary cancer of renal carcinoma, soft tissue cancer, breast carcinoma, lung.Because these combinations comprise at least two kinds of active antineoplastic agents, so it is application of each combinations of substances of using with Asia treatment effective dose that the application of such combination also provides in the wherein said material one or both, thereby has reduced the toxicity relevant with each chemotherapeutics.
When carrying out chemotherapy, the multiple material with different action modes generally is to use as the part of chemotherapy " cocktail ".Can predict combination of the present invention will be as the cocktail part of chemotherapy, and wherein said chemotherapy cocktail can comprise one or more other antitumor agents according to the neoplastic character of being treated.For example, the invention still further relates to the application of this mTOR inhibitor/alkylating agent combination and the associating of other chemotherapeutics, wherein said other chemotherapeutics such as antimetabolite (that is, 5-fluorouracil, floxuridine, thioguanine, cytosine arabinoside, NSC-118218,6-mercaptopurine, methotrexate, gemcitabine, capecitabine, pentostatin, trimetrexate or carat Qu Bin); Hormonal substance (that is, estramustine, tamoxifen, toremifene, anastrozole or letrozole); Antibiotic (that is, plicamycin, bleomycin, mitoxantrone, idarubicin, dactinomycin, mitomycin or daunorubicin); Immunomodulator (that is, interferon, IL-2 or BCG); Antimitotic agent (that is, vinblastine, vincristine, teniposide or Vinorelbine); Topoisomerase enzyme inhibitor (that is, holder pool for may, irinotecan, etoposide or amycin); With other material (that is, hydroxyurea, trastuzumab, altretamine, retuximab, paclitaxel, docetaxel, L-Asnase or gemtuzumabozogamicin).
The used assembled scheme of the present invention can carry out administration simultaneously or can carry out administration with interlace scheme, and said interlace scheme is that the mTOR inhibitor carries out administration in the different time in the chemotherapy process except that alkylating agent.This time difference between two kinds of material administrations can be a few minutes, several hours, several days, a few week or longer time.Therefore, term " combination " not necessarily refers to simultaneously or with the single dose form administration, but each component can be carried out administration period in required treatment.Said material can also carry out administration by different approach.For example, add in the combination of alkylating agent, predict the mTOR inhibitor and can carry out oral or parenteral at the mTOR inhibitor, preferred parenteral, and alkylating agent can carry out administration by parenteral, oral or other acceptable method.These combinations can be by administration every day, be administered once weekly or even be administered once in every month.As typical chemotherapy regimen, can after several weeks, repeat chemotherapy process, and can carry out the administration of two kinds of materials, or can make amendment according to reaction according to identical time range.
In chemotherapy common do, this dosage is supervised closely according to many factors by the doctor who treats, wherein said factor comprises the order of severity of disease, the reaction of disease, any toxicity, patient's age, health condition and other complication or the treatment relevant with treatment.
According to the result of the combination gained that adds alkylating agent with CCI-779, the intravenous input dosage that the mTOR inhibitor is initial is designed to about 0.1 to 100mg/m
2, be preferably about 2.5 to 70mg/m
2Also preferably this mTOR inhibitor is carried out administration, generally in 30 minutes, it is carried out administration, and the jede Woche administration approximately once by intravenous administration.The predose of alkylating agent component will depend on component utilized, and begin based on the experience of doctor to selected material.After one or more treatment cycle, can raise or reduce this dosage according to the result of gained and the side effect that is observed.
For can for the alkylating agent of commercial sources acquisition, using prior dosage form, can distribute dosage as required.Perhaps, can maybe can not prepare such material according to the pharmaceutical operation of standard by the alkylating agent that commercial sources obtains.The oral formulations that comprises reactive compound of the present invention can comprise any oral form commonly used, comprises tablet, capsule, cheek agent, dragee, lozenge and liquid oral (suspension or solution).Capsule can comprise the mixture of reactive compound (various active chemical compound) and inert filler and/or diluent such as pharmaceutically useful starch (for example corn, Rhizoma Solani tuber osi or tapioca), sugar, artificial sweetener, Powderd cellulose, as crystalline cellulose and microcrystalline Cellulose, flour, gelatin, natural gum or the like.Useful tablet formulation can be by conventional compression; wet granulation or dry granulation are prepared; and can use acceptable diluents; binding agent; lubricant; disintegrating agent; surface modifier (comprising surfactant); suspensoid or stabilizing agent, it comprises magnesium stearate without limitation; stearic acid; Pulvis Talci; sodium lauryl sulfate; microcrystalline Cellulose; carboxymethylcellulose calcium; polyvinylpyrrolidone; gelatin; alginic acid; arabic gum; xanthan gum; sodium citrate; composition silicate; calcium carbonate; glycine; dextrin; sucrose; sorbitol; dicalcium phosphate; calcium sulfate; lactose; Kaolin; mannitol; sodium chloride; Pulvis Talci; dried starch and powdered sugar.Preferred surface modifier comprises nonionic and anionic surface modifier.The representative example of surface modifier comprises poloxamer 188, benzalkonium chloride, calcium stearate, 16/octadecanol, cetomacrogol emulsifing wax, Isosorbide Dinitrate, silica sol, phosphate ester, sodium lauryl sulphate, aluminium-magnesium silicate and triethanolamine without limitation.The oral formulations of this paper can also utilize standard delay or time release formulation to change the absorption of reactive compound (various active chemical compound).This oral formulations can also comprise the active component of use in water or fruit juice, wherein can comprise solubilizing agent or emulsifying agent as required.
Wish in some cases this chemical compound is directly delivered medicine to trachea with the form of aerosol.
This chemical compound can also carry out administration by parenteral or intraperitoneal administration.The solution of the reactive compound of these free alkalis or pharmaceutical acceptable salt or suspension can be prepared in the water that is mixed with surfactant such as hydroxypropyl cellulose aptly.Can also glycerol, liquid polyethylene glycol with and the oils mixture in carry out the preparation of dispersion.Under common storage and application conditions, these preparations comprise antiseptic to prevent microbial growth.
The medicament forms that is suitable for injecting application comprises aseptic aqueous solution or dispersion and is used for the sterilized powder of the interim preparation of this sterile injectable solution or dispersion.In all situations, this form must be aseptic, and must have certain fluidity to have syringeability preferably.It must stablize and must be able to prevent the contamination of microorganism such as antibacterial and fungus under manufacturing and condition of storage.Its carrier can be to comprise for example water, ethanol, polyhydric alcohol (for example glycerol, propylene glycol and liquid polyethylene glycol), its suitable mixture and the solvent or the disperse medium of vegetable oil.
For purpose of the present invention, percutaneous dosing should be understood to include all administrations of being undertaken by body surface and the interior layer that comprises the body passageway of epidermis and mucosal tissue.Such administration can be carried out with the form of lotion, cream, foam, suspension, solution and suppository (rectum and vaginal suppository) with chemical compound of the present invention or its pharmaceutically useful salt.
Percutaneous dosing can be finished by the transdermal patch that use comprises this reactive compound and carrier, wherein said carrier is inert for this reactive compound, and is nontoxic and can carry out the whole body administration so that said material is gone into blood by skin absorbs to skin.This carrier can be that any form is as frost and ointment, paste, gel and closing device.Frost and ointment can be the viscous fluid or the semisolid emulsion of oil-in-water or water-in-oil type.Also be suitable for by being dispersed in the paste that the oil that comprises this active component or the absorbent powder in the hydrophilic petroleum form.Can use various closing devices that this active component is discharged in the blood, said device comprises this active component and comprises or do not comprise the bank of carrier or comprise the semipermeable membrane of the substrate of this active component as being covered with.Other closing device is known in the literature.
Suppository formulations can be prepared with traditional material, comprises Oleum Cocois (can to wherein adding or do not add wax to change the fusing point of suppository) and glycerol.Can also use water miscible suppository base such as various molecular weight polyethylene glycol.
Claims (48)
1. method that the mammiferous tumor that needs are treated is treated, it comprises the combination that comprises mTOR inhibitor and anti-tumor alkylating agent of using effective dose to said mammal.
2. the method for claim 1, wherein said tumor is a renal carcinoma.
3. the method for claim 1, wherein said tumor is the soft tissue cancer.
4. the method for claim 1, wherein said tumor is a breast carcinoma.
5. the method for claim 1, wherein said tumor is the neuroendocrine tumor of lung.
6. the method for claim 1, wherein said tumor is a cervical cancer.
7. the method for claim 1, wherein said tumor is a uterus carcinoma.
8. the method for claim 1, wherein said tumor is a neck cancer.
9. the method for claim 1, wherein said tumor is a glioma.
10. the method for claim 1, wherein said tumor is a nonsmall-cell lung cancer.
11. the method for claim 1, wherein said tumor is a carcinoma of prostate.
12. the method for claim 1, wherein said tumor is a cancer of pancreas.
13. the method for claim 1, wherein said tumor is a lymphoma.
14. the method for claim 1, wherein said tumor is a melanoma.
15. the method for claim 1, wherein said tumor is a small cell lung cancer.
16. the method for claim 1, wherein said tumor is an ovarian cancer.
17. the method for claim 1, wherein said tumor is a colon cancer.
18. the method for claim 1, wherein said tumor is an esophageal carcinoma.
19. the method for claim 1, wherein said tumor is a gastric cancer.
20. the method for claim 1, wherein said tumor is a leukemia.
21. the method for claim 1, wherein said tumor is a colorectal carcinoma.
22. the method for claim 1, wherein said tumor are unknown primary cancers.
23. as any described method in the claim 1 to 22, wherein said anti-tumor alkylating agent is selected from meclorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiophene for group, mitomycin, busulfan, chlorethyl cyclohexyl nitrosourea, carmustine, methylbenzyl hydrazine, temozolomide, cisplatin and carboplatin.
24. method that the mammiferous tumor that needs are treated is treated, it comprise to said mammal use the combination that comprises mTOR inhibitor and anti-tumor alkylating agent of effective dose, said thereafter mTOR inhibitor, alkylating agent or mTOR inhibitor and alkylating agent all are provided with Asia treatment effective dose.
25. method as claimed in claim 24, wherein said mTOR inhibitor is provided with Asia treatment effective dose.
26. method as claimed in claim 24, wherein said alkylating agent is provided with Asia treatment effective dose.
27. method as claimed in claim 24, wherein said mTOR inhibitor and alkylating agent all are provided with Asia treatment effective dose.
28. as any described method in the claim 1 to 27, wherein said mTOR inhibitor is a rapamycin.
29. method as claimed in claim 28, wherein said rapamycin is a rapamycin.
30. method as claimed in claim 28, wherein said rapamycin are 42-O-(2-hydroxyl) ethyl rapamycin.
31. method as claimed in claim 28, wherein said rapamycin is CCI-779.
32. an antitumor combination, it comprises the mTOR inhibitor and the anti-tumor alkylating agent of effective dose.
33. combination as claimed in claim 32, wherein said mTOR inhibitor is a rapamycin.
34. combination as claimed in claim 33, wherein said rapamycin is a rapamycin.
35. combination as claimed in claim 33, wherein said rapamycin are 42-O-(2-hydroxyl) ethyl rapamycin.
36. combination as claimed in claim 33, wherein said rapamycin is CCI-779.
37.mTOR inhibitor and the anti-tumor alkylating agent application in the medicine of preparation treatment tumor.
38. application as claimed in claim 37, wherein said tumor are neuroendocrine tumor, cervical cancer, uterus carcinoma, a neck cancer, glioma, nonsmall-cell lung cancer, carcinoma of prostate, cancer of pancreas, lymphoma, melanoma, small cell lung cancer, ovarian cancer, colon cancer, esophageal carcinoma, gastric cancer, leukemia, colorectal carcinoma or the unknown primary cancer of renal carcinoma, soft tissue cancer, breast carcinoma, lung.
39. as claim 37 or 38 described application, wherein said anti-tumor alkylating agent is selected from meclorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiophene for group, mitomycin, busulfan, chlorethyl cyclohexyl nitrosourea, carmustine, methylbenzyl hydrazine, temozolomide, cisplatin and carboplatin.
40. as any described application in the claim 37 to 39, wherein said mTOR inhibitor, alkylating agent or mTOR inhibitor and alkylating agent all are provided with Asia treatment effective dose.
41. as any described application in the claim 37 to 40, wherein said mTOR inhibitor is a rapamycin.
42. application as claimed in claim 41, wherein said rapamycin is a rapamycin.
43. application as claimed in claim 41, wherein said rapamycin are 42-O-(2-hydroxyl) ethyl rapamycin.
44. application as claimed in claim 41, wherein said rapamycin is CCI-779.
45. a product that comprises mTOR inhibitor and anti-tumor alkylating agent is used for the treatment of mammal tumor with while, combination formulations form independent or sequential use.
46. product as claimed in claim 45, wherein said mTOR inhibitor is CCI-779.
47. pharmaceutical composition that comprises mTOR inhibitor, anti-tumor alkylating agent and pharmaceutically suitable carrier.
48. compositions as claimed in claim 47, wherein said mTOR inhibitor is CCI-779.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29523601P | 2001-06-01 | 2001-06-01 | |
US29519001P | 2001-06-01 | 2001-06-01 | |
US60/295,236 | 2001-06-01 | ||
US60/295,190 | 2001-06-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1646120A true CN1646120A (en) | 2005-07-27 |
CN100496485C CN100496485C (en) | 2009-06-10 |
Family
ID=26968972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB02811048XA Expired - Fee Related CN100496485C (en) | 2001-06-01 | 2002-05-29 | Antineoplastic combinations |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1392286A2 (en) |
JP (1) | JP2004532883A (en) |
KR (1) | KR100875611B1 (en) |
CN (1) | CN100496485C (en) |
AU (2) | AU2002259309B2 (en) |
BR (1) | BR0210101A (en) |
CA (1) | CA2447732A1 (en) |
CO (1) | CO5540294A2 (en) |
EA (1) | EA007530B1 (en) |
HU (1) | HUP0400006A2 (en) |
IL (1) | IL158800A0 (en) |
MX (1) | MXPA03010907A (en) |
NO (1) | NO20035317L (en) |
NZ (1) | NZ529877A (en) |
PL (1) | PL367267A1 (en) |
SG (1) | SG153647A1 (en) |
WO (1) | WO2002098416A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102671196A (en) * | 2006-04-05 | 2012-09-19 | 诺瓦提斯公司 | Combinations of therapeutic agents for treating cancer |
CN103446138A (en) * | 2005-11-21 | 2013-12-18 | 诺瓦提斯公司 | Neuroendocrine tumor treatment using mtor inhibitors |
CN103721189A (en) * | 2013-12-27 | 2014-04-16 | 刘玉含 | Meningeoma nursing medicine and preparation method thereof |
CN105168204A (en) * | 2015-09-06 | 2015-12-23 | 江志鑫 | Pharmaceutical composition containing mitomycin and capable of resisting colon cancer |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ307637B6 (en) * | 2001-02-19 | 2019-01-23 | Novartis Ag | 40-O- (2-Hydroxyethyl) rapamycin as the only active ingredient in the treatment |
UA83484C2 (en) * | 2003-03-05 | 2008-07-25 | Уайт | Method for treating breast cancer using combination of rapamycin derivative and aromatase inhibitor, pharmaceutical composition |
AR046194A1 (en) | 2003-11-04 | 2005-11-30 | Mayo Foundation | TREATMENT METHOD OF MANTO CELL LYMPHOMA |
CN102886045A (en) | 2005-02-03 | 2013-01-23 | 综合医院公司 | Method for treating gefitinib resistant cancer |
AR057854A1 (en) * | 2005-11-04 | 2007-12-19 | Wyeth Corp | ANTINEOPLASTIC COMBINATIONS WITH MTOR INHIBITOR, HERCEPTINE AND / OR HKI-272 (E) -N- {4- [3-CHLORINE-4- (2-PIRIDINILMETOXI) ANILINO] -3-CIANO-7-ETOXI-6-QUINOLINIL} -4- (DIMETHYLAMINE) -2-BUTENAMIDE |
GB0523658D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
US20090023768A1 (en) * | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
MX2009009537A (en) * | 2007-03-07 | 2009-09-16 | Abraxis Bioscience Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent. |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
EP2915532B1 (en) | 2008-06-17 | 2016-10-19 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
JP5681108B2 (en) | 2008-08-04 | 2015-03-04 | ワイス・エルエルシー | 4-Anilino-3-cyanoquinoline and capecitabine antineoplastic combination |
RU2011139363A (en) | 2009-04-06 | 2013-05-20 | ВАЙЕТ ЭлЭлСи | BREAST CANCER TREATMENT SCHEME USING NERATINIB |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
DE69209183T2 (en) * | 1991-06-18 | 1996-08-08 | American Home Prod | Use of rapamycin to treat adult T cell lymphoma / leukemia |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
CZ307637B6 (en) * | 2001-02-19 | 2019-01-23 | Novartis Ag | 40-O- (2-Hydroxyethyl) rapamycin as the only active ingredient in the treatment |
-
2002
- 2002-05-29 CN CNB02811048XA patent/CN100496485C/en not_active Expired - Fee Related
- 2002-05-29 EP EP02729310A patent/EP1392286A2/en not_active Ceased
- 2002-05-29 KR KR1020037015721A patent/KR100875611B1/en not_active IP Right Cessation
- 2002-05-29 CA CA002447732A patent/CA2447732A1/en not_active Abandoned
- 2002-05-29 MX MXPA03010907A patent/MXPA03010907A/en not_active Application Discontinuation
- 2002-05-29 HU HU0400006A patent/HUP0400006A2/en unknown
- 2002-05-29 BR BR0210101-7A patent/BR0210101A/en not_active Application Discontinuation
- 2002-05-29 SG SG200507698-9A patent/SG153647A1/en unknown
- 2002-05-29 NZ NZ529877A patent/NZ529877A/en unknown
- 2002-05-29 JP JP2003501455A patent/JP2004532883A/en not_active Withdrawn
- 2002-05-29 WO PCT/US2002/016737 patent/WO2002098416A2/en active Application Filing
- 2002-05-29 PL PL02367267A patent/PL367267A1/en not_active Application Discontinuation
- 2002-05-29 EA EA200301319A patent/EA007530B1/en not_active IP Right Cessation
- 2002-05-29 IL IL15880002A patent/IL158800A0/en unknown
- 2002-05-29 AU AU2002259309A patent/AU2002259309B2/en not_active Ceased
-
2003
- 2003-11-26 CO CO03104435A patent/CO5540294A2/en not_active Application Discontinuation
- 2003-11-28 NO NO20035317A patent/NO20035317L/en not_active Application Discontinuation
-
2008
- 2008-06-18 AU AU2008202690A patent/AU2008202690A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103446138A (en) * | 2005-11-21 | 2013-12-18 | 诺瓦提斯公司 | Neuroendocrine tumor treatment using mtor inhibitors |
CN102671196A (en) * | 2006-04-05 | 2012-09-19 | 诺瓦提斯公司 | Combinations of therapeutic agents for treating cancer |
CN102671196B (en) * | 2006-04-05 | 2014-12-03 | 诺华股份有限公司 | Combinations of therapeutic agents for treating cancer |
CN103721189A (en) * | 2013-12-27 | 2014-04-16 | 刘玉含 | Meningeoma nursing medicine and preparation method thereof |
CN105168204A (en) * | 2015-09-06 | 2015-12-23 | 江志鑫 | Pharmaceutical composition containing mitomycin and capable of resisting colon cancer |
Also Published As
Publication number | Publication date |
---|---|
SG153647A1 (en) | 2009-07-29 |
NO20035317D0 (en) | 2003-11-28 |
MXPA03010907A (en) | 2004-02-17 |
EP1392286A2 (en) | 2004-03-03 |
BR0210101A (en) | 2004-06-08 |
CN100496485C (en) | 2009-06-10 |
CA2447732A1 (en) | 2002-12-12 |
WO2002098416A2 (en) | 2002-12-12 |
NZ529877A (en) | 2006-08-31 |
PL367267A1 (en) | 2005-02-21 |
EA200301319A1 (en) | 2004-04-29 |
IL158800A0 (en) | 2004-05-12 |
AU2002259309B2 (en) | 2008-05-01 |
EA007530B1 (en) | 2006-10-27 |
KR20040025923A (en) | 2004-03-26 |
HUP0400006A2 (en) | 2004-04-28 |
WO2002098416A3 (en) | 2003-03-13 |
CO5540294A2 (en) | 2005-07-29 |
AU2008202690A1 (en) | 2008-07-10 |
JP2004532883A (en) | 2004-10-28 |
NO20035317L (en) | 2003-12-22 |
KR100875611B1 (en) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1309421C (en) | Antineoplastic combinations | |
CN100496485C (en) | Antineoplastic combinations | |
KR100827942B1 (en) | Pharmaceutical composition comprising rapamycin 42-ester with 3-hydroxy-2-hydroxymethyl-2-methylpropionic acidCCI-779 as an antineoplastic agent | |
AU2016355268B2 (en) | Combination therapy of tetracyclic quinolone analogs for treating cancer | |
US20030008923A1 (en) | Antineoplastic combinations | |
US20060030547A1 (en) | Antineoplastic combinations | |
JP2022088616A (en) | Method for preparing drug for use in treatment of malignant tumors selected from group consisting of recurrent gliomas and advanced secondary brain tumors | |
RU2605335C2 (en) | Combination therapy with an antitumor alkaloid | |
US20070105887A1 (en) | Antineoplastic combinations of temsirolimus and sunitinib malate | |
CN102369011A (en) | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | |
AU2002259309A1 (en) | Antineoplastic combinations | |
CN104513257A (en) | Substituted urea derivatives and application thereof in drugs | |
AU2011240001B2 (en) | Combination of organic compounds | |
RU2341261C2 (en) | Compositions containing epothilones, and application thereof for carcinoid syndrome treatment | |
RU2501559C2 (en) | Anticancer activity of cci-779 in papillary renal cell carcinoma | |
KR20100131474A (en) | Improved anticancer treatments | |
RU2358731C2 (en) | Cci-779 for amphicyte lymphoma treatment | |
EA021117B1 (en) | Method for producing a water-soluble pharmaceutical composition of an antibiotic from the group consisting of rifamycins, and pharmaceutical composition for treating tuberculosis and diseases associated with helicobacter pylori | |
RU2195937C1 (en) | Combined antituberculosis preparation (rizobutol) | |
CN116490177A (en) | Pathway modulator, pharmaceutical composition containing the same, use thereof, and therapeutic method using the same | |
CN109381451A (en) | Magnesium threonate and combinations thereof for treating tumour |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090610 Termination date: 20110529 |